BostonSight and LV Prasad Eye Institute Announce Study on the Effect of PROSE and Scleral Lenses on Mental Health

Tuesday, August 11 2026 | 13 h 31 min | News

BostonSight® has announced the launch of a new prospective clinical trial designed to evaluate how PROSE® treatment and scleral lenses may impact mental health outcomes. This marks an important milestone in BostonSight’s ongoing research into the benefits of specialty lenses beyond the cornea and ocular surface.

The IRB‑approved study is being conducted in partnership with the L V Prasad Eye Institute (LVPEI) in Hyderabad, India. LVPEI is a long‑standing BostonSight partner, providing PROSE treatment and BostonSight SCLERAL distribution throughout India and the surrounding region. The study will follow patients who receive PROSE treatment or who are fitted with BostonSight SCLERAL lenses to assess measurable mental health outcomes.

PROSE treatment is a custom, non‑surgical medical approach that helps people living with corneal and ocular surface disease achieve lasting comfort, clarity and improved quality of life. BostonSight SCLERAL is a commercially available lens used for mild to moderate corneal and ocular surface conditions.

Evaluating Mental Health Outcomes in Specialty Lens Wearers

“IRB approval is an important milestone that confirms this study meets established ethical and regulatory standards. We are excited to move forward with this important study to evaluate quantifiable mental health outcomes associated with these specialty lenses,” said Dr. Prashant Garg, Executive Chair, LVPEI.

“Mental health is an often overlooked or underappreciated part of caring for ocular surface disease patients,” added Daniel Brocks, MD, Chief Medical Officer at BostonSight. “The often‑dramatic effect that improved vision, ocular comfort and ocular health can have on mental health is something we see every day. With this study, we hope to objectively measure this effect, which could further support earlier intervention with PROSE treatment and specialty lenses in a patient’s eye care journey.”

Study Overview

• Target Population: New PROSE and BostonSight SCLERAL patients
• Primary Objective: Identify correlations between quantifiable mental health outcomes and specialty lens treatment
• Study Design:
  • Mental health measured using the PHQ‑9 questionnaire
  • Ocular surface symptoms evaluated with OSDI
  • Visual functioning assessed with VFQ‑25
  • Analysis will explore how changes in mental health relate to vision‑centered questionnaire scores
• Expected Impact: Increase awareness of mental health challenges associated with ocular surface disease and promote earlier intervention with PROSE treatment

For questions or additional information, contact Estelle Crowley, Clinical Research Coordinator, at ecrowley@bostonsight.org or 781‑726‑7337.

Click HERE for the press release.

Want to see more like this article? Click here to subscribe to our FREE print magazines and e-newsletters!